Events
Janssen and Gilead Sciences continue to showcase the potential treatment abilities of their respective HIV treatments. This morning the two companies released 96-week data demonstrating their efficacy and safety that was presented during an HIV conference in the United Kingdom.
In the wake of a significant number of journal articles being retracted due to falsified data, the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is halting a clinical trial that is testing an experimental stem cell therapy for heart patients.
Event convenes industry leaders and patient advocates to debate and discuss best practices
Not on My Watch Aims to Shine a Light on the Importance of an Informed, Proactive Approach to Treatment
Neos Therapeutics, Inc. today announced that it will present new data for Adzenys XR-ODT (amphetamine) Extended-Release Orally-Disintegrating Tablets, at the 65th Annual Meeting of the American Academy of Child & Adolescent Psychiatry(AACAP), being held October 22-27, 2018 at the Washington State Convention Center in Seattle, Washington.
Immunicum AB (publ; IMMU.ST) announced today that the Company will host two investor events in October. At both events, Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session.
Combioxin SA announced an Oral Presentation highlighting successful first-in-human clinical results with CAL02 in severe pneumonia patients in ICU, at the ESICM’s annual congress, LIVES 2018, in Paris today.
Oxurion NV announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview at the Ophthalmology Innovation Summit (OIS@AAO 2018) at 3:55 p.m. CDT on Thursday, Oct. 25, 2018 in Chicago, Illinois.
Polyphor presented new efficacy data on its immuno-oncology candidate, balixafortide, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
Regeneus Ltd provides the Company’s quarterly results for the period ended 30 September 2018.
PRESS RELEASES